Clinical Trial Update: Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating aflibercept in combination with standard R-CHOP chemotherapy in first-line non-Hodgkin B-cell lymphoma; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Adriamycin (doxorubicin)
• Cytoxan (cyclophosphamide)
• Deltasone (prednisone)
• Oncovin (vincristine)
• Rituxan (rituximab)
• Zaltrap (ramucirumab)

Snippet

Sponsor: Sanofi | Conditions: Lymphoma, Non-Hodgkin | Phase 1 | Status: COMPLETED